Mediwound

Yahoo Finance • 6 days ago

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL® Findings support ongoing VALUE Phase III study and planned... Full story

Yahoo Finance • last month

MediWound Ltd. Q4 2025 Earnings Call Summary

MediWound Ltd. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Drivers The company successfully commissioned an expanded manufacturing facility, increasing NexoBrid production capacity sixfold to meet anticipat... Full story

Yahoo Finance • 5 months ago

Here are the major earnings before the open Thursday

Major earnings expected before the bell on Thursday include: * Walmart (WMT [https://seekingalpha.com/symbol/WMT]) * ZIM Integrated Shipping Services Ltd. (ZIM [https://seekingalpha.com/symbol/ZIM]) * NetEase (NTES [https://seekinga... Full story

Yahoo Finance • 5 months ago

MediWound to Report Third Quarter 2025 Financial Results

MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global... Full story

Yahoo Finance • 5 months ago

MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®

MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid® Newly commissioned facility marks a significant development toward a sixfold production capacity increase ahead of full operational readin... Full story

Yahoo Finance • 6 months ago

MediWound announces $30M registered direct offering

MediWound (MDWD) “announced that it has entered into a definitive securities purchase agreement led by a prominent U.S.-based mutual fund and other healthcare-focused investors for the sale and purchase of 1,734,105 ordinary shares of the... Full story

Yahoo Finance • 6 months ago

MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares

MediWoundAnnounces$30 Million Registered Direct Offering of Ordinary Shares YAVNE, Israel, September 29, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation enzymatic therapeutics for tissue repair, t... Full story

Yahoo Finance • 7 months ago

MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia

MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia TGA Approves NexoBrid® for Adults and Children; Manufacturing Readiness Positions MediWound for 2025 Launch and Asia-Pacific Expansion YAVNE, Israel, Septem... Full story

Yahoo Finance • 8 months ago

MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, ho... Full story

Yahoo Finance • 8 months ago

MediWound Ltd (NASDAQ:MDWD) Reports Mixed Q2 2025 Results with Revenue Growth but Wider-Than-Expected Losses

MediWound Ltd (NASDAQ:MDWD [https://www.chartmill.com/stock/quote/MDWD]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company posted revenue of $5.7 million, a 43% s... Full story

Yahoo Finance • 8 months ago

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers Post hoc analysis published in Advances in Wound Care, provides clinical evidence supporting wo... Full story

Yahoo Finance • 8 months ago

MediWound to Report Second Quarter 2025 Financial Results

MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-gen... Full story

Yahoo Finance • 11 months ago

MediWound to Report First Quarter 2025 Financial Results

YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended... Full story

Yahoo Finance • last year

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in mid-2026 Strategic research collaborat... Full story

Yahoo Finance • 2 years ago

MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand EscharEx® Phase III study preparations progressing; Protocol submission to FDA expected in first quarter 2024 Ca... Full story

Yahoo Finance • 2 years ago

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik... Full story

Yahoo Finance • 2 years ago

MediWound to Report Third Quarter 2023 Financial Results

YAVNE, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the th... Full story

Yahoo Finance • 2 years ago

MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients

YAVNE, Israel, Nov. 13, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the Committee for Medi... Full story

Yahoo Finance • 2 years ago

MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe

YAVNE, Israel, and DENKENDORF, Germany, Nov. 08, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, and PolyMedics Inn... Full story

Yahoo Finance • 3 years ago

MediWound Announces Collaboration with 3M on EscharEx® Phase III Study

YAVNE, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced collaboration with 3M Healt... Full story